[Federal Register Volume 60, Number 216 (Wednesday, November 8, 1995)]
[Notices]
[Pages 56345-56346]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-27636]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


Notice of Meeting; AIDS Research Program Evaluation Working Group

    Notice is hereby given of the meeting of the NIH AIDS Research 
Program Evaluation Working Group Area Review Panel on Drug Discovery on 
November 29-30, 1995 at the Doubletree Hotel at Lincoln Center, 5410 
LBJ Freeway, Dallas, Texas 75240. The meeting will be open to the 
public from 9:00 am to 12:00 pm on November 29, and the closed portion 
will be from 1:00 pm to 6:00 pm on November 29, and 7:00 a.m. to 10:30 
am on November 30.
    The NIH Revitalization Act of 1993 authorizes the Office of AIDS 
Research (OAR) to evaluate the AIDS research activities of NIH. The NIH 
AIDS Research Program Evaluation Working Group was established by the 
OAR to carry out this major evaluation initiative, reviewing and 
assessing each of the components of the NIH AIDS research endeavor to 
determine whether those components are appropriately designed and 
coordinated to answer the critical scientific questions to lead to 
better treatments, preventions, and a cure for AIDS. Six Area Review 
Panels were also established to address the following research areas: 
Natural History and Epidemiology; Etiology and 

[[Page 56346]]
Pathogenesis; Clinical Trials; Drug Discovery; Vaccines; and Behavioral 
and Social Sciences Research.
    The purpose of the meeting is to seek input from individuals and 
organizations interested in the evaluation of AIDS research in the 
areas of therapeutics research as it pertains to drug discovery. 
Examples of areas under consideration by the panel include basic and 
applied research in HIV and opportunistic diseases, molecular and 
structural research, targeted drug discovery programs and animal 
models. The NIH AIDS Research Program Evaluation Working Group will 
develop recommendations to be made to the Office of AIDS Research 
Advisory Council that address the overall NIH AIDS research 
initiatives, both intramural and extramural, and identify long-range 
goals in the relevant areas of science. These recommendations will 
provide the framework for future planning and budget development of the 
NIH AIDS research program.
    There will be a closed session from 1:00 pm to 6:00 pm on November 
29, and 7:00 a.m. to 10:30 am on November 30, to update the Panel 
members on privileged information on institute and center grant and 
contract portfolios.
    The open session from 9:00 am to 12:00 pm will begin with a brief 
overview of panel activities by members of the panel. The remainder of 
the meeting will be devoted to presentations from individuals and 
organizations. The session is open to the public; however, attendance 
may be limited by seat availability.
    Comments should be confined to statements related to the current 
status NIH AIDS research in the areas of drug discovery for HIV-1 and 
its associated sequelae and recommendations for consideration by the 
panel in assessing and reviewing the relevant research in these areas.
    Only one representative of an organization may present oral 
comments. Each speaker will be permitted 5 minutes for their 
presentation. Interested individuals and representatives of 
organizations must submit a letter of intent to present comments and 
three (3) typewritten copies of the presentation, along with a brief 
description of the organization represented, to the attention of Dr. 
Judith Feinberg, Office of AIDS Research, NIH, 31 Center Drive, MSC 
2340, Building 31, Room 5C08, Bethesda, MD 20892-2340, (301) 496-0358, 
FAX: (301) 402-8638. Letters of intent and copies of presentations must 
be received no later than 5:00 pm on Wednesday, November 22.
    Any person attending the meeting who does not request an 
opportunity to speak in advance of the meeting will be allowed to make 
a brief oral presentation at the conclusion of the meeting, if time 
permits, and at the discretion of the Chairperson.
    Individuals wishing to provide only written statements should send 
three (3) typewritten copies of their comments, including a brief 
description of their organization, to the above address no later than 5 
pm on November 22. Statements submitted after that date will be 
accepted. They may not, however, be made available to the Area Review 
Panel prior to the meeting, though they will be provided subsequently 
as written testimony.
    Individuals who plan to attend and need special assistance, such as 
sign language interpretation or other reasonable accommodations, should 
contact Dr. Feinberg in advance of the meeting.

    Dated: November 3, 1995.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 95-27636 Filed 11-7-95; 8:45 am]
BILLING CODE 4140-01-M